Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Dopaminergics (dopamine precursor) / dopa decarboxylase inhibitors. |
| Generic Name : | Levodopa, benserazide |
| Drug description : | Madopar Capsules: '62.5' blue/ grey capsules; '125' blue/pink capsules; '250' blue/caramel capsules. All capsules marked ROCHE. Madopar Dispersible: white scored tablets marked with strength and ROCHE. Madopar CR: green/blue controlled-release capsules controlled-release capsules marked ROCHE. |
| Presentation : | Madopar Capsules: '62.5', levodopa 50mg, benserazide (as hydrochloride) 12.5mg. '125', levodopa 100mg, benserazide (as hydrochloride) 25mg. '250', levodopa 200mg, benserazide (as hydrochloride) 50mg. Madopar Dispersible: '62.5', levodopa 50mg, benserazide (as hydrochloride) 12.5mg. '125', levodopa 100mg, benserazide (as hydrochloride) 25mg. Madopar CR: Levodopa 100mg, benserazide (as hydrochloride) 25mg. |
| Indications : | Kemadrin is indicated for the treatment and symptomatic relief of all forms of Parkinson's disease e.g. idiopathic (paralysis agitans), postencephalitic and arteriosclerotic disease. Kemadrin is also indicated for the control of extrapyramidal symptoms induced by neuroleptic drugs including pseudo-parkinsonism, acute dystonic reactions and akathisia. |
| Adult Dosage : | Madopar Capsules: Under 25 years, not recommended; over 25 years, patients not receiving levodopa, initially 1 x '62.5' three or four times daily after meals increasing by 1 x '125' daily once or twice weekly. Usual maintenance, 4 - 8 x '125' daily in divided doses. See data sheet. Madopar CR: Under 25 years, not recommended; over 25 years, patients not receiving levodopa: initially 1 three times daily with meals, titrated according to individual requirements; see data sheet. Patients receiving levodopa: see |
| Child Dosage : | Not recommended. |
| Elderly Dosage : | Madopar Capsules: Initially 1 x '62.5' once or twice daily increasing by 1 x '62.5' every third or fourth day. |
| Contra Indications : | Severe psychoses, narrow angle glaucoma, history of malignant melanoma. Pregnancy. Lactation. |
| Special Precautions : | Cardiovascular, hepatic, renal, pulmonary or endocrine disease. Peptic ulceration. Psychiatric disturbances. Wide angle glaucoma. Osteomalacia. Monitor blood values and hepatic, renal and cardiovascular function. Withdraw 12 - 48 hours before elective surgery. |
| Interactions : | Drugs affecting central amines. MAOIs, antihypertensives and sympathomimetics, ferrous sulphate. Antacids with Madopar CR. |
| Adverse Reactions : | Nausea, vomiting, anorexia. Postural hypotension. Involuntary movements. Cardiac and CNS disturbances. Urine discolouration. Haemolytic anaemia (rare). |
| Manufacturer : | Roche |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org